In vitro and in vivo studies showed that blocking CD47-SIRPα interaction by using anti-CD47 mAbs enhanced macrophage-mediated phagocytosis, improved survival, and reduced tumor burden in human GBM engrafted mice.4 Here, CD47 is linked to neoplasm.